← Leaderboards
David M. Lubman
University Of Michigan At Ann Arbor
$15,307,348
Attributed
$17,393,849
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,393,849 · 12
By mechanism
R01$13,751,447 · 6
U01$1,984,690 · 1
R21$1,657,712 · 5
Top collaborators
- Yehia Mechref4 shared
- Tujin Shi4 shared
- Grace Y. Chen2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Laura Beretta$16,561,253
- Mark L Day$6,682,269
- Jorge A Marrero$3,014,574
- Neehar Dilip Parikh$2,316,206
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsSamplingMalignant NeoplasmsBaseTumorMass Spectrum AnalysisDetectionSerumLectinMonitorCancer EtiologyStructureBiological MarkersPolysaccharidesCessation Of LifePeptidesEarly DiagnosisGlycosylationSurvival RateDatabasesGlycoproteinsMeasurementSpecificityNeoplastic Cell
Grant awards (60)
Universal Internal Standard for Reproducible Accurate Quantification of Exosome Protein Markers$433,021
R01 · FY2025 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$403,688
R01 · FY2025 · CA · contact PI
Universal Internal Standard for Reproducible Accurate Quantification of Exosome Protein Markers$448,610
R01 · FY2024 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$145,907
R01 · FY2024 · CA · contact PI
Universal Internal Standard for Reproducible Accurate Quantification of Exosome Protein Markers$468,551
R01 · FY2023 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$358,211
R01 · FY2023 · CA · contact PI
Universal Internal Standard for Reproducible Accurate Quantification of Exosome Protein Markers$466,913
R01 · FY2022 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$361,793
R01 · FY2022 · CA · contact PI
Supplemental for Detection of Glycopeptides of MCI in Patient Serum$274,488
R01 · FY2022 · CA · contact PI
Screening of Glycan Markers in Serum for Early Detection of HCC in Different Etiologies of Disease$473,414
U01 · FY2021 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$384,252
R01 · FY2021 · CA · contact PI
Screening of Glycan Markers in Serum for Early Detection of HCC in Different Etiologies of Disease$493,563
U01 · FY2020 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$360,861
R01 · FY2020 · CA · contact PI
Screening of Glycan Markers in Serum for Early Detection of HCC in Different Etiologies of Disease$488,235
U01 · FY2019 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$350,034
R01 · FY2019 · CA · contact PI
Screening of Glycan Markers in Serum for Early Detection of HCC in Different Etiologies of Disease$529,478
U01 · FY2018 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$360,861
R01 · FY2018 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$360,861
R01 · FY2017 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$374,611
R01 · FY2016 · CA · contact PI
Differential Mapping of Stem Cells in Tumors$289,547
R01 · FY2016 · GM · contact PI
Therapeutic Monitoring in Pancreatic Cancer Using an Exosome Based Mass Spec Assay$168,563
R21 · FY2016 · CA · contact PI
Identifying bacterial regulators of tumorigenesis$168,563
R21 · FY2016 · CA
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$452,487
R01 · FY2015 · CA · contact PI
Differential Mapping of Stem Cells in Tumors$289,741
R01 · FY2015 · GM · contact PI
Identifying bacterial regulators of tumorigenesis$202,655
R21 · FY2015 · CA
Therapeutic Monitoring in Pancreatic Cancer Using an Exosome Based Mass Spec Assay$202,438
R21 · FY2015 · CA · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$353,565
R01 · FY2014 · CA · contact PI
Differential Mapping of Stem Cells in Tumors$289,931
R01 · FY2014 · GM · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$342,631
R01 · FY2013 · CA · contact PI
Serum glycoprotein markers of cancer using an ion mobility/mass spec approach$294,190
R01 · FY2013 · CA · contact PI
Differential Mapping of Stem Cells in Tumors$290,114
R01 · FY2013 · GM · contact PI
Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach$378,375
R01 · FY2012 · CA · contact PI
Serum glycoprotein markers of cancer using an ion mobility/mass spec approach$313,429
R01 · FY2012 · CA · contact PI
Differential Mapping of Posttranslational Modifications in Tumor Cells$89,990
R01 · FY2012 · GM · contact PI
Serum glycoprotein markers of cancer using an ion mobility/mass spec approach$312,911
R01 · FY2011 · CA · contact PI
Differential Mapping of Posttranslational Modifications in Tumor Cells$264,115
R01 · FY2010 · GM · contact PI
Differential Mapping of Posttranslational Modifications in Tumor Cells$267,119
R01 · FY2009 · GM · contact PI
Proteomic Pathways for Pancreatic Cancer Stem Cells$198,025
R21 · FY2009 · CA · contact PI
Differential Mapping of Posttranslational Modifications in Tumor Cells$267,432
R01 · FY2008 · GM · contact PI
Protein Microarrays for the Humoral Response in Cancer$225,622
R01 · FY2008 · CA · contact PI
A Lectin Glycoarray Approach for Markers of Pancreatic Cancer$182,400
R21 · FY2008 · CA · contact PI
Proteomic Pathways for Pancreatic Cancer Stem Cells$168,872
R21 · FY2008 · CA · contact PI
Differential Mapping of Posttranslational Modifications in Tumor Cells$294,272
R01 · FY2007 · GM · contact PI
Protein Microarrays for the Humoral Response in Cancer$283,881
R01 · FY2007 · CA · contact PI
Liquid Proteomics for Marker Screening of Ovarian Cancer$258,227
R01 · FY2007 · CA · contact PI
A Lectin Glycoarray Approach for Markers of Pancreatic Cancer$152,000
R21 · FY2007 · CA · contact PI
Protein Microarrays for the Humoral Response in Cancer$292,360
R01 · FY2006 · CA · contact PI
Liquid Proteomics for Marker Screening of Ovarian Cancer$265,940
R01 · FY2006 · CA · contact PI
Protein Microarrays for the Humoral Response in Cancer$299,395
R01 · FY2005 · CA
Liquid Proteomics for Marker Screening of Ovarian Cancer$272,340
R01 · FY2005 · CA
Microsequencing in an Ion Trap/reTOF Device$151,000
R01 · FY2005 · GM
Protein Microarrays for the Humoral Response in Cancer$299,395
R01 · FY2004 · CA
Liquid Proteomics for Marker Screening of Ovarian Cancer$272,340
R01 · FY2004 · CA
Microsequencing in an Ion Trap/reTOF Device$151,000
R01 · FY2004 · GM
Liquid Proteomics for Marker Screening of Ovarian Cancer$271,450
R01 · FY2003 · CA
Microsequencing in an Ion Trap/reTOF Device$151,000
R01 · FY2003 · GM
Microsequencing in an Ion Trap/reTOF Device$176,000
R01 · FY2002 · GM
DIFFERENTIAL PROTEIN EXPRESSION BY MALDI TOF MS$100,821
R21 · FY2002 · CA
DIFFERENTIAL PROTEIN EXPRESSION BY MALDI TOF MS$113,375
R21 · FY2001 · CA
METHODS FOR MICROSEQUENCING IN AN ION TRAP$38,986
R01 · FY2000 · GM